Wednesday, October 9

Opening Symposium: Keynote Lecture
Chairperson: Kah-Whye Peng

17:30-21:00 Registration open

18:00-19:00 Welcome Dinner

19:00-19:10 Welcome to IOVC 2019
Kah-Whye Peng
Mayo Clinic, Rochester, MN, USA

Keynote Lecture by Tomoki Todo

19:15-19:30 Introduction by Robert Martuza
Massachusetts General Hospital, Boston, MA, USA

19:30-20:15 INV01: Tomoki Todo
The University of Toyko, Japan
Clinical development of oncolytic herpes virus G47Δ

20:15-22:00 Welcome Reception
Drinks and Snacks
Thursday, October 10

Scientific session 1: Virus and Host Interactions / Innate Immunity
Chairpersons: Grant McFadden and Martine Lamfers

08:00-17:00 Registration

07:30-08:30 Breakfast

08:30-08:55 INV02: Valery Grdzelishvili
University of North Carolina at Charlotte, NC, USA
Understanding and breaking multiple mechanisms of resistance of pancreatic cancer cells to oncolytic viruses

08:55-09:20 INV03: Glen Barber
University of Miami, FL, USA
STING-Dependent Innate Immune Signaling, Viral Oncolysis and Cancer

09:20-09:35 Oral 1: Dimitry Shayakhmetov
Emory University, Atlanta, GA, USA
Structure-guided engineering of oncolytic adenovirus for systemic cancer therapy

09:35-09:50 Oral 2: Tae Ho Hwang
Pusan National University, South Korea
Targeting subtypes of circulating myeloid cells during oncolytic vaccinia virus therapy

09:50-10:05 Oral 3: Hiroshi Nakashima
Brigham and Women’s Hospital, Harvard Medical School, MA, USA
In vivo analyses of tumor, immune cells and oncolytic viruses to dissect factors important for efficacy

10:05-10:35 Coffee break
# Programme

## Thursday, October 10

**Scientific session 2:**  
**Virus and Host Interactions / Adaptive Immunity**  
*Chairpersons:* Tomoki Todo and Alan Melcher

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Institution</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:40-11:05</td>
<td>INV04: Jing Qing</td>
<td>Jing Qing</td>
<td>Amgen, San Francisco, CA, USA</td>
<td>Mechanisms of OncoVEXmGM-CSF-induced durable and systemic anti-tumor immunity in preclinical models</td>
</tr>
<tr>
<td>11:05-11:30</td>
<td>INV05: Kevin Harrington</td>
<td>Kevin Harrington</td>
<td>Institute of Cancer Research, London, UK</td>
<td>Pharmacological modulation of oncolytic virotherapy: In search of synthetically lethal combinations</td>
</tr>
<tr>
<td>11:30-11:45</td>
<td>Oral 4: Miguel Angel Muñoz-Alía</td>
<td>Miguel Angel Muñoz-Alía</td>
<td>Mayo Clinic, Rochester, MN, USA</td>
<td>A CD46-specific measles virus resistant to neutralization by measles-immune human serum</td>
</tr>
<tr>
<td>11:45-12:00</td>
<td>Oral 5: Louisa Chard Dunmall</td>
<td>Louisa Chard Dunmall</td>
<td>Queen Mary University of London, UK</td>
<td>An intravenously injectable oncolytic Vaccinia virus, QM007, demonstrates potent anti-tumor efficacy and sensitises tumors to α-PD1 therapy in murine models of pancreatic cancer</td>
</tr>
<tr>
<td>12:00-12:15</td>
<td>Oral 6: Takafumi Nakamura</td>
<td>Takafumi Nakamura</td>
<td>Tottori University, Japan</td>
<td>Tumor-specific replication-competent oncolytic vaccinia virus with stealth effect by engineering viral glycoprotein B5R</td>
</tr>
<tr>
<td>12:15-12:30</td>
<td>Oral 7: Jean Simon Diallo</td>
<td>Jean Simon Diallo</td>
<td>Ottawa Hospital Research Institute, Canada</td>
<td>Antibody drug conjugate enhancement of oncolytic virotherapy</td>
</tr>
<tr>
<td>12:30-13:30</td>
<td>Lunch (provided)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Thursday, October 10

**Scientific session 3: Engineered Viruses**  
Chairpersons: John Bell and Nori Kasahara

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Researcher</th>
<th>Institution/Location</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30-13:55</td>
<td>INV06: Liang Deng</td>
<td>Memorial Sloan Kettering Cancer Center, NYC, USA</td>
<td>Rational engineering of vaccinia viruses for cancer immunotherapy</td>
</tr>
<tr>
<td>13:55-14:10</td>
<td>Oral 8: Matthew Robertson</td>
<td>University of Minnesota, Minneapolis, MN, USA</td>
<td>Clinical translation of adenovirus-based radiotherapy and imaging for pancreatic cancer</td>
</tr>
<tr>
<td>14:10-14:25</td>
<td>Oral 9: Michael Bergman</td>
<td>Medical University of Vienna, Austria</td>
<td>Optimization of the oncolytic influenza virus by exchange of the viral hemagglutinin rather than by expression of a T-cell stimulating cytokine</td>
</tr>
<tr>
<td>14:25-14:40</td>
<td>Oral 10: Karol Budzik</td>
<td>Mayo Clinic, Rochester, MN, USA</td>
<td>Simian foamy virus – a new retroviral platform for cancer therapy</td>
</tr>
<tr>
<td>14:45-15:10</td>
<td>INV07: Dimitry Zamarin</td>
<td>Memorial Sloan Kettering Cancer Center, NYC, USA</td>
<td>Modulation of Newcastle Disease Virus-activated anti-tumor immunity</td>
</tr>
<tr>
<td>15:10-15:25</td>
<td>Oral 11: John Christie</td>
<td>Arizona State University, Tempe, AZ, USA</td>
<td>Exploiting TNF-armed myxoma virus in a syngeneic murine lung sarcoma metastasis model</td>
</tr>
<tr>
<td>15:25-15:40</td>
<td>Oral 12: Masato Yamamoto</td>
<td>University of Minnesota, Minneapolis, MN, USA</td>
<td>AdMG-MYOGp(S)-E1-5/3F, MYOG promoter controlled oncolytic adenovirus, selectively kills rhabdomyosarcoma</td>
</tr>
<tr>
<td>15:40-15:55</td>
<td>Oral 13: Ahmet Hazini</td>
<td>Technische Universität Berlin, Germany</td>
<td>Oncolytic avirulent coxsackievirus B3 strain PD induces anti-tumor immunity and prevents development of cancer cachexia</td>
</tr>
<tr>
<td>15:55-16:30</td>
<td>Coffee break</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Thursday, October 10

**Scientific session 4: The Great Debate**

**Chairperson:** Kerry Fisher

16:30-18:00

The Great Debate

Oncolytic viruses work better if they encode tumor antigens

**Yes: Richard Vile**

*Mayo Clinic, Rochester, MN, USA*

**No: Len Seymour**

*Oxford University, UK*

18:30-21:00

**Conference Dinner**

Transport leaving from the venue at 18:15

---

Friday, October 11

**Scientific session 5: Engineered Viruses and Cancer Vaccines**

**Chairperson:** Eva Galanis

08:00-17:00

**Registration**

07:30-08:30

**Breakfast**

08:30-08:55

**INV08: Lelia Delamarre**

*Genentech, San Francisco, CA, USA*

Harnessing neoantigens for cancer immunotherapy

08:55-09:20

**INV09: Autumn Schulze**

*Mayo Clinic, Rochester, MN, USA*

Synthetic infectious RNA for oncolytic virotherapy

09:20-09:35

**Oral 14: Amanda Huff**

*Mayo Clinic, Rochester, MN, USA*

Vesicular stomatitis virus expressing destabilized tumor associated antigens to improve anti-tumor T cell responses
# Programme

## Friday, October 11

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:35-9:50</td>
<td><strong>Oral 15:</strong> Dipongkor Saha&lt;br&gt;&lt;i&gt;Texas Tech University, San Marcos, TX, USA&lt;/i&gt;&lt;br&gt;Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma</td>
</tr>
<tr>
<td>9:50-10:05</td>
<td><strong>Oral 16:</strong> Aladar Szalay&lt;br&gt;&lt;i&gt;University of Wuerzburg, Germany&lt;/i&gt;&lt;br&gt;Clinical cancer therapy trial: Autologous stem cells as oncolytic vaccine carriers for immunotherapy of cancer in human patients</td>
</tr>
<tr>
<td>10:05-10:20</td>
<td><strong>Coffee break</strong></td>
</tr>
<tr>
<td><strong>Scientific session 6:</strong> Keynote Lecture</td>
<td></td>
</tr>
<tr>
<td>10:20-11:25</td>
<td><strong>Keynote lecture by Rosalind Carter</strong>&lt;br&gt;Introduction by Stephen Russell&lt;br&gt;&lt;i&gt;Mayo Clinic, Rochester, MN, USA&lt;/i&gt;</td>
</tr>
<tr>
<td>11:30-11:55</td>
<td><strong>INV10:</strong> Rosalind Carter&lt;br&gt;&lt;i&gt;CDC, Atlanta, GA, USA&lt;/i&gt;&lt;br&gt;rVSV Ebola vaccine: cold chain and logistical challenges for field implementation</td>
</tr>
<tr>
<td><strong>Scientific session 7:</strong> Clinical Trials</td>
<td></td>
</tr>
<tr>
<td>11:55-12:20</td>
<td><strong>INV11:</strong> Paola Grandi&lt;br&gt;&lt;i&gt;Cold Genesys, Irvine, CA, USA&lt;/i&gt;&lt;br&gt;Treatment of bladder cancer using CG0070</td>
</tr>
<tr>
<td>12:20-12:35</td>
<td><strong>Oral 17:</strong> Shruthi Naik&lt;br&gt;&lt;iVyriad, Rochester, MN, USA&lt;/i&gt;&lt;br&gt;Neoadjuvant intravenous oncolytic virotherapy in canines with spontaneous osteosarcoma</td>
</tr>
</tbody>
</table>
### Friday, October 11

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:35-13:30</td>
<td><strong>Lunch (provided)</strong></td>
</tr>
<tr>
<td>13:30-13:50</td>
<td><strong>Scientific session 8: Industry Session</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Chairpersons:</strong> Frank Tufaro and Chae Ok Yun</td>
</tr>
<tr>
<td>13:30-13:50</td>
<td><strong>INV13: Chae Ok Yun</strong></td>
</tr>
<tr>
<td></td>
<td><em>Hanyang University, Genemedicine Inc, South Korea</em></td>
</tr>
<tr>
<td></td>
<td>Exploring hydrogel system to enhance the therapeutic efficacy of oncolytic adenovirus</td>
</tr>
<tr>
<td>13:50-14:10</td>
<td><strong>INV14: Grey Wilkinson</strong></td>
</tr>
<tr>
<td></td>
<td><em>Oncolytics Biotech, Calgary, Canada</em></td>
</tr>
<tr>
<td></td>
<td>Systemic administration of oncolytic reovirus, pelareorep, a metanalysis on the efficiency of tumor delivery</td>
</tr>
<tr>
<td>14:10-14:30</td>
<td><strong>INV15: Brian Champion</strong></td>
</tr>
<tr>
<td></td>
<td><em>Psioxus Therapeutics, Oxford, UK</em></td>
</tr>
<tr>
<td></td>
<td>Tumor-specific immunogene (T-SIGN) therapy for cancer: preclinical and clinical development of viruses designed to deliver combination immunotherapy locally within the tumor microenvironment</td>
</tr>
<tr>
<td>14:30-14:45</td>
<td><strong>Oral 18: Talia Biran</strong></td>
</tr>
<tr>
<td></td>
<td><em>Oncolys Biopharma, NJ, USA</em></td>
</tr>
<tr>
<td></td>
<td>Phase I dose-escalation study of endoscopic intratumoral injection of OBP-301 (telomelysin) with radiotherapy in esophageal cancer patients unfit for standard treatments</td>
</tr>
<tr>
<td>14:45-15:00</td>
<td><strong>Oral 19: Steve Thorne</strong></td>
</tr>
<tr>
<td></td>
<td><em>Western Oncolytics, Pittsburg, PA, USA</em></td>
</tr>
<tr>
<td></td>
<td>VET-S3, a next generation clinical oncolytic vaccinia virus</td>
</tr>
<tr>
<td>15:00-15:15</td>
<td><strong>Oral 20: Edward Kennedy</strong></td>
</tr>
<tr>
<td></td>
<td><em>Oncorus, Cambridge, MA, USA</em></td>
</tr>
<tr>
<td></td>
<td>ONCR-177, an oncolytic HSV designed to safely and potently activate systemic anti-tumor immunity</td>
</tr>
<tr>
<td>15:15-15:30</td>
<td><strong>Oral 21: Guido Wollmann</strong></td>
</tr>
<tr>
<td></td>
<td><em>University of Innsbruck, Viratherapeutics, Austria</em></td>
</tr>
<tr>
<td></td>
<td>Virotherapy with VSV-GP in a syngeneic lung cancer model is driven by oncolysis rather than antitumor immunity despite strong immune activation in the tumor-micro environment</td>
</tr>
</tbody>
</table>
Friday, October 11

15:30-18:00  **Poster session**
Wine and Cheese

Saturday, October 12

**Scientific session 9: Personalized OV Therapy**
**Chairpersons:** Brian Lichty and Laura Evgin

08:00-17:00  **Registration**

07:30-08:30  **Breakfast**

08:30-08:55  **INV16: Martine Lamfers**
_Erasmus MC, Rotterdam, The Netherlands_  
Development of patient-derived glioblastoma model systems to predict response to OV therapy

08:55-09:20  **INV17: Eva Galanis**
_Mayo Clinic, Rochester, MN, USA_  
Optimizing delivery and personalizing virotherapy treatment: the measles experience

09:20-09:35  **Oral 22: Nicholas Durham**
_AstraZeneca, Rockville, MD, USA_  
Newcastle disease virus in human derived tumors: PDX modeling of viral replication and immune induction

09:35-09:50  **Oral 23: Hannah Lesch**
_Kuopio Center for Gene and Cell Therapy, Finland_  
Adherent and suspension platforms for virus production

09:50-10:30  **Coffee break**
Saturday, October 12

**Scientific session 10: GBM focus session and panel discussion**
*Chairpersons:* Nino Chiocca and Bob Martuza

10:30-10:55 **INV18: Nino Chiocca**
*B Brigham and Women’s Hospital, Harvard Medical School, MA, USA*
Clinical trials of immunovirotherapy in recurrent glioblastoma

11:00-11:20 **INV19: Annick Desjardins**
*Duke University, Durham, NC, USA*
TBC

11:20-11:40 **INV20: Doug Jolly**
*Tocagen, San Francisco, CA, USA*
Immune mechanism of action of Toc 511, a retroviral replicating vector, and 5-FC preclinically and clinically

11:40-12:00 **INV21: Frank Tufaro**
*DNAtrix, Santa Fe, CA, USA*
Development of DNX-2401 (Tastadenoturev) for recurrent GBM: a clinical update

12:00-12:30 **Panel Discussion**
*Chairpersons:* Nino Chiocca and Robert Martuza
*Panel members:* Annick Desjardins, Frank Tufaro, Doug Jolly, Tomoki Todo

12:45-13:45 **Lunch (provided)**

**Scientific session 11: Tumor Microenvironment**
*Chairpersons:* Autumn Schulze and Sam Rabkin

14:00-14:25 **INV22: Balveen Kaur**
*The University of Texas Health, Houston, TX, USA*
PTEN expression by an oncolytic herpesvirus directs T-cell mediated tumor clearance

14:25-14:50 **INV23: Eric Bartee**
*Medical University of South Carolina, Charleston, SC, USA*
Initiating, maintaining, and augmenting anti-tumor immunity during oncolytic therapy
Saturday, October 12

14:50-15:05  **Oral 24: Susanne Warner**  
*Beckman Research Institute, City of Hope, Duarte, CA, USA*  
Combination of immune checkpoint inhibition and recombinant orthopoxvirus (CF33-luc) enhances tumor regression despite initially attenuated viral replication

15:05-15:20  **Oral 25: Nadine van Montfoort**  
*Leiden University Medical Center, The Netherlands*  
Oncolytic reovirus sensitizes immune-silent pancreatic tumors for CD3-bispecific antibody therapy

15:20-15:50  **Coffee break**

---

**Scientific session 12: Activating the Immune System**  
**Chairpersons:** Kah-Whye Peng and Tomoki Todo

16:00-16:25  **INV24: John Bell**  
*Ottawa Health Research Institute, Canada*  
Planting bombs inside tumours

16:25-16:50  **INV25: Gabriella Campadelli-Fiume**  
*University of Bologna, Italy*  
Second generation fully virulent retargeted oHSVs prime for checkpoint blockade and promote anti-tumor vaccination

16:50-17:15  **INV26: Stephen Russell**  
*Mayo Clinic, Vyriad, Rochester, MN, USA*  
Inflaming tumors with systemic VSV therapy

17:15-17:20  **Introduction to IOVC 2020**  
Tomoki Todo, IOVC2020 Conference President

17:30-19:00  **IOVC Committee Meeting**

19:00-23:00  **Farewell Dinner and Dance**  
*Music by: Brian Kinney and Band*  

---

Golden Virus Award

Charles Conrad Memorial Award